SAB Biotherapeutics, Inc. (SABSW) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $10.50M | +18.0% |
| 2024 | $8.90M | -84.3% |
| 2023 | $56.57M | +275.9% |
| 2022 | $15.05M | -54.7% |
| 2021 | $33.21M | +163.3% |
| 2020 | $12.61M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $10.50M | +18.0% |
| 2024 | $8.90M | -84.3% |
| 2023 | $56.57M | +275.9% |
| 2022 | $15.05M | -54.7% |
| 2021 | $33.21M | +163.3% |
| 2020 | $12.61M | — |